pulmonary embolism - search results
If you're not happy with the results, please do another search
SCAI 2023: Mechanical thrombectomy improves symptoms and quality of life in pulmonary embolism patients...
Six-month outcomes from the FLASH registry have shown that patients with pulmonary embolism who were treated with mechanical thrombectomy showed significant improvement in symptoms,...
New data underscore benefits of Penumbra’s Indigo for submassive pulmonary embolisms regardless of clot...
In a new subgroup analysis of the EXTRACT-PE trial, the Indigo aspiration system (Penumbra) was effective at improving clinical outcomes for submassive pulmonary embolism...
Magneto Thrombectomy Solutions announces successful first-in-human results for treatment of pulmonary embolism
Magneto Thrombectomy Solutions (Magneto), a medical devices company developing thrombectomy solutions for the treatment of ischaemic stroke and pulmonary embolism, presented successful first-in-human (FIH)...
Anticoagulants effective for pulmonary embolism resolution in hospitalised COVID-19 patients
Anticoagulants alone are associated with a high rate of resolution of pulmonary embolism (PE) in patients with acute PE and COVID-19 infection. This was...
Viz.ai launches two new AI-powered modules for pulmonary embolism and aortic disease
Viz.ai has announced the US commercial launch of its AI-powered modules for pulmonary embolism and aortic disease. Debuting at VEITHsymposium 2021 (16–20 November, Orlando, USA), the...
Penumbra’s newest generation of Indigo aspiration system receives FDA clearance for pulmonary embolism
Penumbra today announced US Food and Drug Administration (FDA) 510(k) clearance for expanded indication of the latest iteration of the Indigo aspiration system, Lightning...
Systematic review finds high risk of deep vein thrombosis and pulmonary embolism in COVID-19...
In a systematic review of the worldwide published data on venous thromboembolism (VTE) in COVID-19 patients, Cihan Ay, Stephan Nopp, and Florian Moik (Medical...
First pulmonary embolism patient treated with “cyclical” aspiration system
Insera Therapeutics’ CLEAR aspiration system has been used for the first time to treat a (human) patient with acute pulmonary embolism (PE). CLEAR, “cyclical...
FDA approves first generics of Eliquis for prophylaxis of DVT and pulmonary embolism
The US Food and Drug Administration (FDA) has announced the approval of two applications for the first generics of Eliquis (apixaban) tablets, to reduce...
EXTRACT-PE trial of aspiration thrombectomy for acute pulmonary embolism meets efficacy and safety endpoints
It has been found by the EXTRACT-PE trial, a multicentre investigation conducted under an investigational device exemption (IDE) from the US Food and Drug...
Thrombolex announces first enrolment in early feasibility and safety study using Bashir endovascular catheter...
Thrombolex has announced the enrolment of the first patient in their Early Feasibility and Safety Study, investigating the Bashir Endovascular Catheter for the treatment...
SUNSET sPE thrombolysis trial presents interim analysis of ultrasound-guided versus standard catheter thrombolysis for...
The Standard vs ultrasound-assisted catheter thrombolysis for submassive pulmonary embolism (SUNSET sPE) trial, is an ongoing randomised, head-to-head, single-blinded clinical trial comparing ultrasound-assisted thrombolysis...
Direct anticoagulant for pulmonary embolism associated with reduced hospital time and costs
New data from the MERCURY PE study have shown that patients with low-risk pulmonary embolism who were treated with the direct oral anticoagulant rivaroxaban,...
Prospective clinical data on the FlowTriever system confirms excellent results in the treatment of...
Inari Medical have announced the presentation of results from its FlowTriever Pulmonary Embolectomy (FLARE) clinical study that evaluated the safety and effectiveness of the...
Study to measure shorter duration EKOS therapy for pulmonary embolism is enrolling
Global specialist healthcare company BTG has highlighted the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients...
Inari Medical announces completion of enrolment in the FLARE study for the treatment of...
Inari Medical has announced that it has completed enrolment of its investigational device exemption (IDE) study. The FlowTriever Pulmonary Embolectomy Clinical Study (FLARE) study...
Angel Catheter demonstrates reduction in clinically-significant and fatal pulmonary embolism
Bio2 Medical has announced the results of the Angel Catheter pivotal study published in the Journal of Vascular and Interventional Radiology. The Angel Catheter...
OPTALYSE PE study demonstrates safety and efficacy of shorter, lower dose EKOS therapy for...
Results from the OPTALYSE PE trial have been presented at the American Thoracic Society International Conference in Washington, DC, USA. The results show that...
High-risk pulmonary embolism patients often go without most effective treatments
In a new study presented at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of...
First pulmonary embolism patients in Hong Kong treated with BTG’s EKOS system
The first Hong Kong-based patients diagnosed with pulmonary embolism have been treated using the newly available BTG EKOS system. The EKOS system includes an...
When to use intervention for deep venous thrombosis and pulmonary embolism
At the 2016 Leipzig Interventional Course meeting (LINC; 26–29 January, Leipzig, Germany), Michael R Jaff, Boston, USA, discussed the challenges facing intervention for deep...
Catheter-directed thrombolysis for pulmonary embolism in the paediatric population
Peter H Lin
Pulmonary embolism in children is a potentially lethal condition and yet is a vastly understudied arena. Autopsy studies show a higher prevalence...
NICE recommends once-daily Lixiana (edoxaban) to treat and prevent adult recurrent deep vein thrombosis...
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help...
SEATTLE II results show no intracranial haemorrhage or no death among pulmonary embolism patients
The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk pulmonary embolism.
NICE publishes final guidance on the use of Eliquis (apixaban) to treat and prevent...
Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of...
What the vascular specialist must know about echo for pulmonary embolism
By David Dudzinski
Transthoracic echocardiography offers real-time information that assists vascular specialists in the diagnostic and prognostic evaluation of acute pulmonary embolism. Specific roles of...
European Commission approves Eliquis (apixaban) for treatment of deep vein thrombosis and pulmonary embolism
Bristol‐Myers Squibb Company and Pfizer have announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary...
Eliquis (apixaban) receives CHMP positive opinion for the treatment of deep vein thrombosis and...
Bristol-Myers Squibb Company and Pfizer have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
FDA approves Pradaxa for treatment of deep venous thrombosis and pulmonary embolism
Boehringer Ingelheim Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep venous...
NICE UK draft guidance recommends rivaroxaban for pulmonary embolism
The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending rivaroxaban (Xarelto, Bayer Healthcare) as a clinically and...
Ultrasound-accelerated thrombolysis shows advantage over anticoagulation alone in submassive pulmonary embolism
Results of the ULTIMA pulmonary embolism trial comparing endovascular therapy to standard of care were presented at the American College of Cardiology meeting in...
Studies support benefit of dabigatran for prevention of recurrent deep vein thrombosis and pulmonary...
The New England Journal of Medicine has published findings from the RE-MEDY and RE-SONATE trials investigating dabigatran etexilate (Pradaxa, Boehringer Ingelheim) in the long-term prevention...
Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism
By Russell Samson
Aspirin finds a role again
Before the advent of more potent heparin, low molecular weight heparins and warfarin, aspirin was used extensively in the...
European commission approves rivaroxaban for the treatment of pulmonary embolism and the prevention of...
Rivaroxaban (Xarelto, Bayer HealthCare) has been approved by the European Commission for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep...
FDA expands use of rivaroxaban to treat deep vein thrombosis or pulmonary embolism
On 2 November, the US Food and Drug Administration (FDA) expanded the approved use of rivaroxaban (Xarelto) to include treating deep vein thrombosis (DVT)...
Rivaroxaban recommended for approval for pulmonary embolism in Europe
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the oral anticoagulant rivaroxaban...
EKOS announces two more pulmonary embolism clinical studies
SEATTLE I and II are intended to further establish the safety and efficacy of ultrasound accelerated thrombolysis for treatment of pulmonary embolism.
Rivaroxaban shows comparable efficacy to standard of care for pulmonary embolism patients
Results of the EINSTEIN-PE study have shown that the oral anticoagulant rivaroxaban (Xarelto, Janssen and Bayer Healthcare) was comparable to today’s standard of care...
Long-term outcomes of percutaneous mechanical thrombectomy for severe pulmonary embolism
Guering Eid-Lidt, Department of Interventional Cardiology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, spoke about long-term outcomes of percutaneous mechanical thrombectomy for...
Are inferior vena cava filters as good as we think in the prevention of...
By Jörn Oliver Balzer
Pulmonary embolism continues to be a major cause of morbidity and mortality in the United States. In most clinical situations, anticoagulation...
EkoSonic receives CE mark to treat massive and sub-massive pulmonary embolism
The EkoSonic system, originally designed to dissolve blood clots in arms and legs, is the new alternative for the treatment of pulmonary embolism; until now, drugs were the only approved treatment.
RESCUE trial shows reduction in segmental and main pulmonary artery occlusions
Robert A Lookstein, who is executive vice chair, Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai Hospital (New...
New study demonstrates IVC filters “safe and effective” in treating venous thromboembolism
Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into...
New mechanical thrombectomy systems unlock possibilities for the treatment of venous thromboembolism
Gerd Grözinger (Tübingen, Germany) chats with Bernhard Gebauer (Berlin, Germany) at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14...
RESCUE trial of the Bashir endovascular catheter demonstrates reduction in pulmonary artery obstruction in...
Thrombolex today presented the final results of its National Institutes of Health (NIH)-sponsored RESCUE trial at TCT 2022 (16–19 September, Boston, USA).
This investigational...
Study finds significant association between low bilirubin levels and venous thromboembolism
A recent paper published by Hakan Duman (Recep Tayyip Erdoğan University, Rize, Turkey) and colleagues in the Journal of Vascular Surgery: Venous and Lymphatic...
GARFIELD-VTE Registry sheds light on global heterogeneity of venous thromboembolism patients, treatment and outcomes
The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress...
AMPLIFY data indicate Eliquis (apixaban) is comparable to conventional therapy in recurrent venous thromboembolism...
Bristol-Myers Squibb and Pfizer have announced results from a post-hoc early time course subanalysis of the phase 3 AMPLIFY (Apixaban for the initial management of...
Edoxaban approved for prevention of stroke and systemic embolism in non-valvular AF and treatment...
Daiichi Sankyo has announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for...
FDA approves Savaysa for reduction of stroke risk in non-valvular atrial fibrillation and for...
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s Savaysa (edoxaban), an oral, once-daily selective factor Xa inhibitor, to reduce the risk...
Phase III study of dabigatran meets primary endpoint for six-month treatment of venous thromboembolism
Boehringer Ingelheim has announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis and/or...
ASPIRE trial shows 34% reduction in major vascular events with aspirin in unprovoked venous...
Low-dose aspirin prevents recurrent venous thromboembolism and major vascular events in patients with first unprovoked venous thromboembolism, results from the ASPIRE randomised controlled trial,...
Computerised checklist offers best preventive strategy for venous thromboembolism
A computerised checklist system designed to help physicians identify and use the best methods of preventing potentially venous thromboembolism (VTE) in hospitalised trauma patients...
Edoxaban significantly reduces risk of venous thromboembolism by half compared to enoxaparin
On 12 December, Daiichi Sankyo announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced...
NICE recommends once-daily Lixiana (edoxaban) for the treatment and prevention of recurrent DVT and...
NICE has issued a Final Appraisal Determination (FAD) for Lixiana (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
FDA clears EkoSonic endovascular system
Ekos Corporation has announced that the US Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.
Vascular News Issue 57 – January 2013 – Digital Edition
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
Vascular News Issue 57 – January 2013 – USA Digital Edition
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the treatment of thrombophlebitis and pulmonary embolism-Profile: Peter Gloviczki
New statement offers advice on treating dangerous, deep blood clots
The American Heart Association's scientific statement offers advice for identifying and treating people with massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension.
FLAME, FLASH and ongoing PEERLESS trials collect “compelling” data for FlowTriever device
Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism...
Akura Medical announces successful first-in-human use of its mechanical thrombectomy platform
Akura Medical announced today it has initiated its first-in-human clinical study of the Akura mechanical thrombectomy platform. A press release notes that the Akura...
ACC 2023: Large bore mechanical thrombectomy reduces adverse outcomes in high-risk PE patients
Large bore mechanical thrombectomy with the FlowTriever system (Inari Medical) in patients with high-risk pulmonary embolism (PE) was associated with a significantly lower occurrence...
AVF 2023: FLASH registry suggests “favourable safety and effectiveness profile” in high-risk PE patients
Among 61 high-risk pulmonary embolism (PE) patients followed through to the 30-day visit in the US cohort of the FLASH registry, no mortalities were...
Viz.ai to expedite patient enrolment in NIH-funded PE-TRACT clinical trial
Viz.ai has announced it will use its Viz Recruit platform to optimise patient enrolment for the National Institutes of Health (NIH)-funded Pulmonary embolism—thrombus removal...
ABRE 36-month results show sustained patency and clinical improvements in complex venous disease patients
Stephen Black (London, UK) talks to Venous News about the key 36-month results from the ABRE study, which evaluated the safety and effectiveness of the Abre venous...
Inari Medical announces first patient enrolment in DEFIANCE trial of the ClotTriever system in...
Inari Medical has announced that the first patient has been enrolled in DEFIANCE, a prospective randomised controlled trial (RCT) comparing the clinical outcomes of...
Meta-analysis of PTS finds one in five risk of long-term symptoms following isolated distal...
A meta-analysis is first to report the pooled risk of post-thrombotic syndrome (PTS) after isolated distal deep vein thrombosis (DVT). Researchers revealed a one...
Real-world analysis confirms benefit of Xarelto in treating CAT as apixaban
Head-to-head observational analysis showed Xarelto as effective in treating cancer-associated thromboembolism (CAT) as apixaban.
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced observational...
FLASH results demonstrate “excellent safety profile” of the FlowTriever system in full US cohort
Results of the FLASH registry demonstrate the “excellent safety profile” of the FlowTriever system (Inari Medical) in 800 “real-world” patients. This is according to...
Penumbra and Asahi Intecc partner to introduce Indigo system to Japan
Penumbra and Asahi Intecc, a Japanese medical device manufacturer, announced that they will collaborate to introduce Penumbra’s Indigo aspiration system into the Japanese market...
Viz.ai receives FDA 510(k) clearance for automated RV/LV analysis algorithm
Viz.ai recently announced it has received US Food and Drug Administration (FDA) 510(k) clearance for an automated right ventricle (RV)/left ventricle (LV) ratio algorithm,...
Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Treatment of critically ill COVID-19 patients with full-dose anticoagulation lowers the risk of venous and arterial clotting complications by 44% compared with the standard...
Inari Medical announces randomised controlled trial evaluating clinical outcomes of the ClotTriever system in...
Inari Medical has announced planned enrolment of the DEFIANCE randomised controlled trial (RCT), which is designed to compare the clinical outcomes of patients with...
Key differences in presentation, outcomes for distal versus proximal DVT uncovered
A new study highlights key differences in clinical features and comorbidities, as well as short-term and also long-term outcomes for patients with distal deep...
RapidAI receives FDA 510(k) clearance for PE Triage & Notification
RapidAI announced today that it has received US Food and Drug Administration (FDA) 510(k) clearance for its Rapid PE Triage & Notification product for...
“Excellent outcomes” for Zilver Vena® venous stent sustained out to three years in challenging...
This advertorial is sponsored by Cook Medical. A downloadable version can be found here.
The Zilver Vena venous self-expanding stent system (Cook Medical) is associated...
Penumbra announces the European launch of the Indigo system with Lightning 7 and Lightning...
Penumbra has announced that its Indigo aspiration system with Lightning 7 and Lightning 12 have secured CE mark and are now commercially available in...
Study finds increased risk of serious blood clots up to six months after COVID-19
A study from Sweden published by The BMJ recently finds an increased risk of deep vein thrombosis (DVT) up to three months after COVID-19 infection,...
Cordis makes strategic investment in E2, a developer of next-generation thrombectomy devices
Cordis has announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the venous thromboembolism (VTE) market...
Biomarkers of heart failure show early reversal with catheter thrombolysis compared to anticoagulation alone...
In a secondary analysis of the SUNSET sPE randomised controlled trial, Efthymios Avgerinos (University of Pittsburgh Medical Centre, Pittsburgh, USA) and colleagues found differences...
Cardiovascular Systems partners with Innova Vascular to develop full line of thrombectomy devices
Cardiovascular Systems Inc (CSI) recently announced it has partnered with Innova Vascular (Innova) to develop a full line of novel thrombectomy devices.
According to a...
First patient enrolled in PEERLESS study of FlowTriever system
Inari Medical has announced that the first patient has been enrolled in PEERLESS—a prospective, randomised controlled trial (RCT) comparing the outcomes of patients with...
Thrombolex announces new interim data from RESCUE trial of the Bashir endovascular catheter
Thrombolex has announced positive results from the prespecified interim analysis of the first 62 evaluable pulmonary embolism (PE) patients enrolled in the investigational RESCUE...
Inari Medical announces six-month FLASH registry interim data
Inari Medical has announced positive acute and long-term interim results from the first 500 pulmonary embolism (PE) patients enrolled in the FlowTriever outcomes registry...
Envveno Medical reports successful completion of first VenoValve surgery for US pivotal trial
Envveno Medical, formerly Hancock Jaffe Laboratories, recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has...
Positive data for the EkoSonic endovascular system presented at VIVA 2021
Boston Scientific announced positive results for the EkoSonic endovascular system (EKOS system) during a late-breaking clinical trial presentation at Vascular Interventional Advances (VIVA) 2021...
Thrombolex announces interim RESCUE results at VIVA 2021
Thrombolex recently announced the results of the RESCUE trial’s prespecified interim analysis, of the first 62 evaluable patients, in a late-breaking clinical trials session...
Inari Medical appoints pulmonologist Victor F Tapson as VP of Medical Affairs
Inari Medical has announced that the company has appointed Victor F Tapson as vice president of Medical Affairs.
Tapson has devoted his medical career to...
Thrombolex announces attendance at The VEINS and VIVA
Thrombolex has announced that it will be attending The VEINS (Venous Endovascular INterventional Strategies) conference (Booth T8) and VIVA (Vascular InterVentional Advances) Physicians conference...
Thromboprophylaxis with anticoagulants “likely effective” at preventing VTE post-vascular surgery, larger trials needed
“Among patients undergoing vascular surgery, thromboprophylaxis with anticoagulants showed a trend towards reduced incidence of VTE when compared to placebo,” Tarek Haykal (Duke...
Global surgery study finds recent or current COVID-19 infection linked to increased risk of...
New research published in Anaesthesia (a journal of the Association of Anaesthetists) shows that venous thromboembolisms (VTEs) are 50% more likely to occur in patients...
Hancock Jaffe presents positive two-year VenoValve data at SVS VAM 2021
Hancock Jaffe Laboratories has announced that promising two-year post-VenoValve implantation data are being presented today at the Society for Vascular Surgery’s Vascular Annual Meeting...
Boston Scientific initiates randomised controlled trial for the EkoSonic endovascular system
Boston Scientific has commenced enrolment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the...
FDA grants Breakthrough Device designation status for Hancock Jaffe’s VenoValve
Hancock Jaffe Laboratories today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation status to the VenoValve, the company’s...
Case report: Recanalisation of chronic iliofemoral venous occlusion in a patient with PAD and...
This advertorial, sponsored by BD, is only available in selected countries and geographies.
A downloadable version of this advertorial can be found here.
In this...
Viz.ai and Avicenna.AI partner to launch AI-driven intelligent care coordination for PE and aortic...
Viz.ai has partnered with Avicenna.AI to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease.
Avicenna.AI’s US...
SVT patients bear “significant risk” of thromboembolic complications at three months, despite anticoagulation
Despite a high rate of initial anticoagulation, patients with isolated superficial vein thrombosis (SVT) are at risk of thromboembolic complications—including recurrent or extended SVT...
Thrombolex receives enhanced indication for use from the FDA
The US Food and Drug Administration (FDA) has enhanced the indications for use of the Bashir endovascular catheter (Thrombolex) and the Bashir Plus endovascular...
Adjunctive compression to standard prophylaxis for postoperative VTE shows benefit in very high-risk patients
Among patients with a Caprini score of ≥11 who received standard prophylaxis for venous thromboembolism (VTE), adjunctive intermittent pneumatic compression (IPC) resulted in a...
Mayo Clinic study provides clarity on use of anticoagulants to treat acute VTE in...
A study by Mayo Clinic researchers provides some clarity on the use of direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, to treat...
Propofol use during catheter-directed interventions for intermediate-risk PE associated with major adverse events
A study suggests avoiding propofol for intraprocedural sedation during catheter-directed interventions (CDIs) for intermediate-risk pulmonary embolism (PE) because it can have detrimental effects. Propofol...
AI triage solution for PE and aortic dissection receives FDA clearance and CE mark
Medical imaging artificial intelligence (AI) specialist Avicenna.AI recently announced that it has received certification in the USA and European Union (EU) for CINA CHEST,...
Further research will soon generate standardised approach to VTE in COVID-19 patients
At VENOUS2021 (17–20 March, virtual), the annual meeting of the American Venous Forum, Geno Merli (Thomas Jefferson University Hospital, Philadelphia, USA) gave a keynote...
Interview: Comprehensive, patient-friendly risk assessment “crucial” to VTE prevention
From the first research linking heparin to a reduction in fatal pulmonary embolism (PE), to the development and refinement of risk assessment tools to...
Hancock Jaffe receives IDE approval to begin VenoValve US pivotal trial
Hancock Jaffe Laboratories recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin...
Inari Medical announces first patient enrolled in FLAME study
Inari Medical has announced the enrolment of the first high-risk pulmonary embolism (PE) patient in the FLAME (FlowTriever for acute massive pulmonary embolism) study....
Meta-analysis: IVC filters should be considered for certain patients at high risk of PE
In a recent meta-analysis, Yang Liu, Huan Lu (Henan Cancer Hospital, Zhengzhou, China), and colleagues found insufficient evidence to prove that inferior vena cava...
First-in-human results for the Bashir endovascular catheter published
Results of a first-in-human study to assess the safety and feasibility of the Bashir endovascular catheter (Thrombolex) for the treatment of acute intermediate-risk pulmonary...
Three-year data add to growing body of clinical evidence in support of VICI Venous...
This advertorial is sponsored by Boston Scientific.
The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement...
A multidisciplinary approach to VTE in COVID-19 patients is warranted
The nature of venous thromboembolism (VTE) in COVID-19 patients is complex, and treatment strategies regarding drug type and dosing continue to evolve, writes Sanjum...
Interview: New registry data provide “high-quality answers” on thromboembolic complications in hospitalised COVID-19 patients
Describing the Northwell CORE-19 registry as “the largest prospective registry of thromboembolic complications in hospitalised COVID-19 patients in the post-hospital discharge period,” lead investigator...
Results published from EXTRACT-PE trial of Penumbra’s Indigo aspiration system
Results from the EXTRACT-PE trial, which found that Penumbra’s Indigo aspiration system met its predefined safety and efficacy endpoints for the treatment of pulmonary...
First-in-human study finds novel laser technique “safe and effective” for embedded filter removal
The excimer laser sheath technique is safe and effective for removing embedded inferior vena cava (IVC) filters refractory to high-force retrieval, the investigators of...
VTE-related factors and elevated bleeding risk associated with IVC filter placement among PERT patients,...
In a recent study, factors related with venous thromboembolism (VTE) severity—including pulmonary embolism response team (PERT) referral from the intensive care unit (ICU) and...
Aidoc and Imbio partner to provide an AI solution to prioritise suspected PE
Aidoc and Imbio have announced a partnership intended to provide an end-to-end artificial intelligence (AI) solution for pulmonary embolism (PE), with the goal of ultimately...
Inari Medical announces presentation of 30-day follow-up results from first patients in FLASH Registry
Inari Medical has announced follow-up results of the first 230 patients enrolled in its FLASH study. FLASH is a real-world registry to study the...
VELTAS document sets out “international standard” for triage of venous patients during pandemic and...
In September 2020, a consensus document outlining the Venous and Lymphatic Triage and Acuity Scale (VELTAS) was co-published in Phlebology and the Journal of...
One-year VIVO results support safety and effectiveness of Zilver Vena venous stent
Results of the VIVO clinical study support the safety and effectiveness of Cook Medical's recently FDA-cleared Zilver Vena venous stent for the treatment of...
FLASH registry: Interim results “reinforce the excellent FlowTriever safety profile”
Catalin Toma (University of Pittsburgh, Pittsburgh, USA) recently presented interim results from the FLASH registry during a late-breaking session at TCT Connect (14–18 October,...
The BASHIR™ Endovascular Catheter: Delivering a complete solution for arterial and venous thrombosis
The BASHIR™ Endovascular Catheter offers a safe and easy-to-use platform technology, creating immediate blood flow, accelerating thrombolysis, and dissolving large volumes of thrombus burden....
Comparable risk of recurrent VTE between patients with unprovoked VTE and patients with cancer
Patients with venous thromboembolism (VTE) carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE...
Society of Interventional Radiology publishes IVC filter guidelines
The Society of Interventional Radiology (SIR) recently published new clinical practice guidelines that provide evidence-based recommendations on the use of inferior vena cava (IVC)...
HOME-PE trial clarifies which patients with acute PE can be managed at home
Patients with acute pulmonary embolism (PE) can be selected for home management using the sPESI score or the Hestia criteria, according to results of...
Study finds death rates from PE have been rising over the past decade
The American Heart Association (AHA) has announced that after nearly a decade of steady decline, the death rate for people with pulmonary embolism (PE)...
First patient enrolled in RESCUE trial of Thrombolex’s Bashir catheter
Thrombolex has announced that it has enrolled the first patient in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary...
Study reports low rates of bleeding and VTE after 12 months of edoxaban treatment
Daiichi Sankyo Europe GmbH has announced results from five analyses of 12-month data from ETNA-VTE (Edoxaban treatment in routine clinical practice in patients with...
Thrombolex receives NIH grant to fund RESCUE trial of Bashir endovascular catheter
Thrombolex has announced that it was awarded a US$3 million Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute...
COVID-19 will have “massive long-term impact” on treatment of venous disease patients
Manj Gohel (Cambridge, UK) is joined by a host of venous experts including Beverley Hunt (London, UK), Stephen Black (London, UK) and Ian Franklin...
CX 2020 LIVE: Overwhelming 91% of specialist audience favours venous stents
A poll of an enthused audience of venous specialists during the CX 2020 LIVE Deep Venous Disease Consensus session found that 91% of them were in...
CX 2020 LIVE addresses latest developments in superficial venous disease
For the first venous session of CX 2020 LIVE, 759 attendees from 79 different countries tuned in. Each audience member could submit their name,...
At six months, adjunctive mechanical thrombectomy associated with higher patency and lower incidence of...
A recent systematic review and meta-analysis showed that, in patients with iliofemoral deep vein thrombosis (DVT), percutaneous mechanical thrombectomy was associated with a higher...
Compression stockings might not be needed to prevent blood clots after surgery
Compression stockings might be unnecessary to prevent blood clots in most patients undergoing non-emergency (elective) surgery, finds a clinical trial published by The BMJ...
New study addresses thromboembolic complications in COVID-19 patients
There is an “urgent need” to improve specific venous thromboembolism (VTE) diagnostic strategies and investigate the efficacy and safety of thromboprophylaxis in ambulatory COVID-19...
Elder statesman of venous disease delivers golfing metaphor for fortitude, wellness
As a podium talk at the annual meeting of the American Venous Forum (VENOUS 2020; 3–6 March, Amelia Island, USA), it represented a bit...
Mechanochemical ablation presents advantages over EVLA in randomised trial of varicose vein patients
Mechanochemical ablation (MOCA) is a superior option to endovenous laser ablation (EVLA) for the treatment of primary varicose veins, according to the findings of...
Virtual ACC: Caravaggio study confirms noninferiority of apixaban to heparin for treatment of cancer-associated...
It has been found that oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-related venous thromboembolism (VTE), as revealed by Giancarlo...
Virtual ACC: Rivaroxaban demonstrates superiority over enoxaparin for prevention of VTE after moderate risk...
Results of PRONOMOS, a randomised, controlled, noninferiority trial, have shown rivaroxaban to be more effective than enoxaparin in the prevention of major venous thromboembolic...
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system (Medtronic) is “a promising therapeutic option for anatomic success at six months”. This study, published in...
First-in-human results for Bashir Endovascular Catheter meet safety and feasibility endpoints
Thrombolex has announced that results of its First-In-Human (FIH) trial confirm the early safety and feasibility of using the Bashir Endovascular Catheter for pharmacomechanical...
No difference in PE incidence between patients treated with IVC filters or anticoagulation alone
In a case-control study of patients with perceived contraindications to anticoagulation, who either received or did not receive inferior vena cava (IVC) filters, no...
Examining the viability of interventional treatment for iliofemoral DVT
ATTRACT compared outcomes following pharmacomechanical thrombolysis (PMT) versus standard medical therapy (SMT), and while no benefit with PMT was demonstrated for femoropopliteal deep vein...
Reviewing evidence for and against IVC filters in 2020
Following the publication of “Another nail in the coffin of vena cava filters” in the British Journal of Surgery, which considered potential problems with...
Improved follow-up measures needed to fill knowledge gap in long-term PE outcomes
“We need to check for signs of recurrence and functional impairment, and follow these patients much more closely,” urged Kenneth Rosenfield (Massachusetts General Hospital,...
Retrospective analysis of UGFS patients shows association with high rate of deep vein occlusions
A retrospective analysis of patients treated with ultrasound-guided foam sclerotherapy (UGFS), published in the January 2020 issue of Phlebology, has found that the frequency...
Argon Medical announces launch of two new IVC filter retrieval kits
Argon Medical Devices has announced the commercial launch of its Single-loop and Triple-loop retrieval kits for sale in the USA. The Single-loop and Triple-loop...
Raghu Kolluri
Following his recent appointment as president of the Society for Vascular Medicine (SVM), Raghu Kolluri (Columbus, USA) speaks to Venous News about how the...
SUNSET sPE thrombolysis trial completes enrolment phase
The “Standard versus ultrasound-assisted catheter thrombolysis for submassive pulmonary embolism” (SUNSET sPE) trial, a randomised, single-blinded clinical trial comparing ultrasound-assisted thrombolysis (USAT) to standard...
Penumbra wins FDA clearance for Indigo Aspiration System
Penumbra has announced US Food and Drug Administration (FDA) 510(k) clearance for expanded indication of the Indigo Aspiration System. As part of the system,...
Astronaut study highlights risk of blood clots in the internal jugular vein during spaceflight
Serena Auñón-Chancellor, clinical associate professor of medicine at Louisiana State University Health, New Orleans School of Medicine’s branch campus, in Baton Rouge, USA, is...
ATTRACT analysis finds improved quality of life for iliofemoral DVT patients treated with PCDT
An analysis of data from the ATTRACT trial, published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVSVL), reveals that quality of...
Insera announces first-in-human treatment of patient with PE using CLEAR aspiration system
Insera Therapeutics announced recently that the first patient with acute pulmonary embolism has been treated with its flagship cyclical aspiration system, CLEAR. Earlier last...
Duplex ultrasound limited for early diagnosis of subclavian vein thrombosis
There are “significant limitations” to the use of duplex ultrasound for the initial evaluation of patients with suspected subclavian vein (SCV) thrombosis, according to...
New trial planned to rigorously test catheter-directed thrombolysis for submassive PE treatment
Clinically relevant outcomes are needed to measure catheter-directed therapy (CDT) against anticoagulation alone to treat submassive pulmonary embolism (PE) patients. Further, CDT’s ability to...
Cook Medical defends its products after another IVC filter company loses court case
A Philadelphia jury has awarded more than US$33 million to a woman who was injured as a result of a defectively designed inferior vena...
Most reinterventions following treatment of iliofemoral DVT could be due to “preventable factors”
Analysing the results of a retrospective, single-centre cohort study conducted at Guys and St Thomas’ Hospital, London, UK, Anna Pouncey (Guys and St Thomas’...
A look at new preliminary guidelines for superficial vein thrombosis
At the European Society of Vascular Surgery annual meeting (ESVS 2019; 24-27 September, Hamburg, Germany), preliminary venous thrombosis guidelines were presented for the first...
New research reveals decreased risk of recurrent VTE in morbidly obese patients with XARELTO
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the publication of new real-world evidence which confirms that XARELTO (rivaroxaban) reduces the risk...
Updated VTE treatment guideline for patients with cancer revealed by ASCO
An updated guideline on the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer has been unveiled by the American Society of...
Catheter-directed thrombolysis treatment for PE may significantly reduce long-term costs with better outcomes
Catheter-directed thrombolysis improves outcomes and long-term cost efficiency for treatment of massive and submassive pulmonary embolism (PE), in comparison to systemic heparin administration. This...
Increased risk of VTE found in critically ill H1N1 patients with acute respiratory distress
A new study has found that intensive care unit patients with swine flu (H1N1) and acute respiratory distress syndrome (ARDS) were 33 times more...
High-intensity focused ultrasound system provides noninvasive treatment of venous insufficiency in feasibility study
A new treatment modality is aiming to take the idea of minimally-invasive procedures to the next level for treatment of varicose veins and venous...
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Thrombolex has announced that the US Food and Drug Administration (FDA) has cleared the Bashir Endovascular Catheter (BEC) for the controlled and selective infusion...
Inari Medical announces publication of FLARE IDE study results
Inari Medical has announced the publication of its 106-patient prospective multicentre FlowTriever Mechanical Pulmonary Embolectomy (FLARE) study for the treatment of intermediate-risk pulmonary embolism...
The optimal pathway for acute deep vein thrombosis treatment involves identification, management and surveillance
Prakash Saha (London, UK), speaking during the Venous and Lymphatic Challenges programme at CX (15–18 April, London, UK), outlined the three key steps to...
VenaSeal maintains safety and efficacy at extended five-year follow-up
The first-ever 60-month data on Medtronic’s VenaSeal closure system were presented on Tuesday, indicating that at five years, treatment with the cyanoacrylate adhesive for...
The vascular community should “be more critical” about accepting new technologies into clinical practice
Speaking at the Charing Cross International Symposium (CX; 15–18 April, London, UK), Isaac Nyamekye (Worcester, UK) presented the results of the 3RF study, which...
CASSINI trial results inconclusive on rivaroxaban effects in high-risk ambulatory cancer patients
The CASSINI trial found that treatment with rivaroxaban did not significantly reduce the incidence of thromboembolism or death caused by thromboembolism in high-risk ambulatory...
First patients enrolled in FLASH registry using the FlowTriever system for PE
Inari Medical has announced the enrolment of the first patient in the FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH) using the company’s...
Rivaroxaban trial finds significant VTE reduction in cancer patients
Results from the Phase 3 CASSINI study contributes new data on the use of oral anticoagulant rivaroxaban (brand name Xarelto, Johnson & Johnson) in...
First successful implantation of the bioconvertible Sentry IVC filter
The world’s first bioconvertible IVC filter commercially offered in the USA (Sentry; from BTG) has been successfully implanted into the first patients outside of...
Boston Scientific announces recommended offer to acquire BTG
Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...
Sentry Bioconvertible IVC filter two-year results show zero tilt or migration
Two-year results for the SENTRY trial were presented at the Vascular Interventional Advances conference (VIVA; 5–8 November, Las Vegas, USA). The prospective, multicentre trial...
BTG to begin European distribution of EKOS Control unit 4.0
BTG has announced that the first EKOS Control Unit 4.0 have been shipped from BTG’s facility in Bothell (Washington, USA) to Europe, where full...
Nationwide study finds no significant differences between rivaroxaban and apixaban for VTE patients
A recent Danish study, examining a nationwide cohort of 8,187 patients with venous thromboembolism (VTE) treated with one of two new oral anticoagulant therapies,...
Current aspects in the management of superficial vein thrombosis
Superficial vein thrombosis is not a rare disease, with an incidence of 0.64 in 1,000 annually.1 The POST, OPTIMEV and STEPH studies have shown...
BTG acquires Novate Medical
BTG has announced it has acquired Novate Medical, a medical device company focused on the prevention of pulmonary embolism in patients at high risk...
Mermaid Medical Group acquires angel technology for vascular space
Mermaid Medical Group, a privately-owned international provider of minimally invasive medical devices, acknowledged a product line addition to its vascular business. As part of...
Study proves need for anticoagulant strategy post discharge for hospitalised, at-risk patients
Alex C Spyropoulos, from Feinstein Institute for Medical Research (New York, USA), has presented an anticoagulant treatment strategy to reduce non-fatal blood clots and...
NexGen Medical Systems launches XCOIL large vessel thrombectomy system
NexGen Medical Systems, Inc., a US medical device company, has announced the successful completion of the first human use of their XCOIL large vessel (18mm)...
PERT Consortium and BTG form strategic partnership
BTG has announced a strategic partnership with the PERT Consortium to advance the science of pulmonary embolism treatment and promote the implementation of PERT...
One-year results of ACCESS PTS study brings “hope” for post-thrombotic syndrome patients
The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as...
One-year data from venous stent registry “promising”
Efficacy data from the Arnsberg Registry at 12 months are promising, with high primary patency rates for a dedicated venous stent.
Presenting the data at...
Early results of iliocaval reconstruction with stents for venous outflow obstruction patients are encouraging
“Endovascular reconstruction of the chronically obstructed iliocaval venous tract with stents is technically feasible, minimally invasive and has an acceptable safety rate, said James...
Published ATTRACT data call into question validity of the Villalta scale
Following the publication of the ATTRACT trial in the New England Journal of Medicine (NEJM) in December 2017, Venous News spoke to experts in...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst lawsuit
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...
Cancer-associated VTE trial sees “lower rate of recurrent VTE with edoxaban compared to dalteparin”
Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in...
Considering venous thrombosis at unusual sites
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis...
Superficial venous thrombosis: Ultrasound, analysis of clot location, and risk factor assessment are “fundamental”
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of...
IVC filter moratorium “not in the best interests of our patients”
Inferior vena cava (IVC) filters have been a highly controversial topic in the field of venous medicine due to the high rates of complications associated with...
Decision-making in the choice of anticoagulants following deep venous stenting
Deep venous stenting has become increasingly used to treat patients with pathological obstruction of venous return in the femoro-iliocaval venous segment following the development of new...
First European advice on deep vein thrombosis published in European Heart Journal
The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European...
Cook Medical’s inferior vena cava filters fare better than ALN’s in retrospective study
Gerard Goh, Radiology, The Alfred Hospital, Melbourne, Australia, reported results from a comparative study of inferior vena cava (IVC) filters at CIRSE 2017 that...
One-year SENTRY trial data offer a “a new perspective” on IVC filters
Twelve-month results from the SENTRY trial evaluating the Sentry bioconvertible inferior vena cava (IVC) filter (Novate) have shown a 0% rate of symptomatic pulmonary...
FDA grants priority review of Xarelto for a 10mg dose to reduce recurrent VTE...
The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...
A novel compression solution for chronic venous insufficiency
Compression therapy is the mainstay of treatment for the symptoms of chronic venous insufficiency (CVI). CVI is treated with compression stockings or multilayer bandaging....
Monocusp: A hybrid-autogenous solution for deep venous insufficiency
Most existing surgical options for symptomatic deep venous insufficiency (DVI) with venous stasis ulcers either fail or provide limited success. Many surgeons consider operating...
Canadian study finds rivaroxaban more effective at preventing recurrent blood clots than aspirin
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of...
Final VIVO-EU results show nearly 90% freedom from occlusion rate for Zilver Vena at...
Gerard O’Sullivan, Department of Radiology, University Hospital Galway, Ireland, presented the results of the VIVO-EU prospective study of the Zilver Vena venous stent (Cook...
Two new real-world studies confirm positive efficacy and safety profile of rivaroxaban in treating...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...
Treatment of superficial vein thrombosis with intermediate doses of tinzaparin
Superficial vein thrombosis (SVT) is a common disease affecting 3–11% of the general population, while in patients with varicose veins the incidence of SVT...
Endothermal heat-induced thrombosis after endovenous laser ablation—a rare complication with safe management
Ovsep Mandzhikian, Moscow, Russia, reports on his centre’s recent experience of endothermal heat-induced thrombosis following treatment with endovenous laser and radial fibres, suggesting that...
Early data from venous stent trials “very promising”
Two 2016 Charing Cross Symposium (CX 2016; 26–29 April, London, UK) presentations in the Venous Challenges Main Programme session have demonstrated the value of...
First patients enrolled in RE-COVERY DVT/PE global observational study on management of DVT and...
Boehringer Ingelheim has announced the enrolment of the first patient in RE-COVERY DVT/PE, a global observational study on the management of deep vein thrombosis...
Patient enrolment begins for PRESERVE study of retrievable inferior vena cava filters
Researchers have activated the first 10 medical sites and enrolled the first nine patients in a study that will determine the safety and effectiveness...
Low rates of major bleeding seen in pivotal trial of rivaroxaban for deep vein...
Bayer and its development partner Janssen Pharmaceuticals presented results from two real world studies—the non-interventional XALIA study in patients with deep vein thrombosis (DVT)...
Real world ETNA registries of new once-daily edoxaban commence in Europe
The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in...
NICE publishes final guidance on the use of Eliquis (apixaban) to treat DVT and...
As part of a 90-day implementation plan, the NHS now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
Use of vena cava filter does not reduce risk of recurrent blood clot for...
Observational studies show a sharp increase in the placement of inferior vena cava filters over the past three decades, including their use as add-on therapy to anticoagulant therapy in patients presenting with a blood clot.
Preliminary data suggest VenaTech convertible filter is a safe and effective temporary filter
Early data from a multicentre, single-arm study that set out to evaluate the safety and effectiveness of a novel approach to inferior vena cava...
Endobronchial forceps effective in retrieval of tip-embedded inferior vena cava filters
Leaving the devices in place risks filter fracture or symptoms from penetration of filter components outside of the vein into adjacent structures, increased risk of new blood clots in the legs, and other complications.
First patient enrolled in US study of Novate’s Sentry IVC filter
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE study.
Secondary analysis of AMPLIFY-EXT examining predictors of hospitalisation presented at ESC congress
Bristol-Myers Squibb and Pfizer have announced results of a pre-specified secondary analysis of the Eliquis phase 3 AMPLIFY-EXT trial (Apixaban after the initial management...
More bleeding with catheter-directed thrombolysis than with standard anticoagulation in deep vein thrombosis
A study published in the Journal of the American Medical Association (JAMA) has found no difference in mortality rates between deep vein thrombosis patients...
Multicentre study evaluates method to improve retrieval rate of inferior vena cava filters
The Heart and Vascular Outcomes Research Institute (HVORI) is collaborating with a number of medical centres to launch the iRetrieve study aimed to improve...
Pradaxa gains EU approval
Boehringer Ingelheim has announced that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep...
Cook Medical begins two studies on inferior vena cava filters
Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava filters.
The first...
Edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative...
Daiichi Sankyo announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two...
ULTIMA trial results published in Circulation
EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation....
Option Elite retrievable vena cava filter receives FDA clearance for a new over-the-wire delivery...
Argon Medical Devices announced that it has received clearance from the US Food and Drug Administration to begin marketing the Option Elite retrievable inferior...
First commercial implantations of Crux vena cava filter announced
The double helical, symmetrical design of the Crux device helps prevent filter tilt, as the helical design self-centres automatically within the vena cava upon deployment. The device offers the Bi-Trieval option of retrieval via either the jugular or femoral vein.
Increasing filter retrieval rates should be a priority
By Brian G DeRubertis
Surgical caval interruption for prevention of fatal pulmonary embolisation had been performed since the 1950s, though the modern era of pulmonary...
New rotational pharmacomechanical thrombectomy device promising for deep vein thrombosis
A new rotational thrombectomy device is safe and effective in the treatment of acute and subacute deep vein thrombosis in a single session of...
New anticoagulant edoxaban shows less bleeding than warfarin in Hokusai-VTE
Results from the Hokusai-VTE study presented at the European Society of Cardiology (ESC) congress have shown that the oral anticoagulant edoxaban was non-inferior to...
CT is the best imaging modality for deep vein thrombosis
Gerard O'Sullivan, Galway, Ireland, CX35 delegates that computed tomography pulmonary angiography (CTPA) and CT venography are his preferred imaging modalities.
“Filter or no filter” during percutaneous endovenous intervention for deep vein thrombosis
By Mohsen Sharifi
Percutaneous endovenous intervention (PEVI) is increasingly being used in the treatment of massive lower extremity deep vein thrombosis. It utilises a variety...
PREFER in VTE European registry enrols first patient
Daiichi Sankyo Europe announced the enrolment of the first patient into the PREFER in VTE (Prevention of thromboembolic events – European registry in venous...
Vascular News Issue 57 – January 2013 USA Edition
Highlights:-Initial experience of total endovascular arch aneurysm exclusion is "encouraging"-Stroke associated with a threefold increased future mortality in CREST-Advances in drug therapy for the...
Vascular News Issue 57 – January 2013
Highlights: -Initial experience of total endovascular arch aneurysm exclusion is "encouraging" -Stroke associated with a threefold increased future mortality in CREST -Advances in drug...
Volcano Corporation to acquire Crux Biomedical
On 3 December, Volcano Corporation announced it has signed an agreement to acquire Crux Biomedical, developer of the Crux VCF System―an inferior vena cava...
New developments in retrievable inferior vena cava filters reviewed
The new Crux inferior vena cava filter can be implanted and retrieved safely and shows a low rate of pulmonary embolism, Anthony J Comerota,...
FDA clears first ever bi-directionally retrievable vena cava filter from Crux Biomedical
The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism....
Ultrasound-accelerated catheter-directed thrombolysis of acute iliofemoral vein thrombosis remains safe
The use of ultrasound-accelerated catheter-directed thrombolysis to treat acute iliofemoral deep vein thrombosis continues to be feasible and safe, according to a study presented...
FDA grants priority review for rivaroxaban supplemental new drug application for the treatment DVT...
The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May...
NICE clinical guideline set to save lives by improving the diagnosis and management of...
New guidance published on 27 June 2012 by the UK National Institute for Health and Clinical Excellence (NICE) aims to reduce the current high...
Angel Catheter is CE-marked
BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached...
Scottish Medicines Consortium accepts rivaroxaban for NHS use in two new indications in Scotland
The anticoagulant rivaroxaban (Bayer HealthCare, Xarelto) has been accepted by the Scottish Medicines Consortium (SMC) for use in eligible patients within NHS Scotland in...
Bioconvertible inferior vena cava filter could eliminate retrieval and complications
David Rosenthal, clinical professor of Surgery at the Medical College of Georgia, and chief of Vascular Surgery, Atlanta Medical Center, Atlanta, USA, presented data...
Charles McCollum
Charles McCollum, University of Manchester, UK, became consultant and senior lecturer in Surgery at the Charing Cross Hospital, London, UK, in 1983, aged 32....
A new low-dose alteplase to restore patency to occluded central venous access devices is...
Boehringer Ingelheim launched Actilyse Cathflo 2mg, a low-dose vial of the thrombolytic alteplase. Actilyse Cathflo 2mg is used to restore the patency of central venous access devices, including those used in haemodialysis.
Venous day at CX 31
Dr Nick Morrison will open the CX Venous Day, on Tuesday 7 April, with a talk on foam sclerotherapy.
Management of deep vein thrombosis
DVT, other than that triggered by trauma or surgery, is now considered to be a chronic disease with a high risk of recurrence.
‘Rapid lysis’ technique could potentially change DVT treatment
Results at the Society of Interventional Radiology's 32nd Annual Scientific Meeting, in Seattle, WA, Dr Mark J Garcia.
Endovenous laser vs RF: Long-term results
Comparing the long term results of endovenous laser and endovenous RFA Therapy
Use of IVUS to optimise outcomes in venous stenting
Intravascular ultrasound (IVUS) imaging technology provides the current gold standard technique for detection and characterisation of venous disease, Erin Murphy writes. In this article,...
